NICE's Trikafta snub could portend another pricing standoff between Vertex and UK officials
Fierce Pharma
NOVEMBER 6, 2023
History may repeat for Vertex Pharmaceuticals in the U.K., where a new decision by the country’s cost-effectiveness gatekeeper threatens to spark another dispute over the cost of lifesaving cystic | Last week, the U.K.'s But the agency stopped short of labeling the medicines cost effective.
272 
Let's personalize your content